BioVU

April 26, 2022

Calculating risk for uterine fibroids

Vanderbilt researchers have constructed a polygenic risk score for uterine fibroids that will be useful for exploring causes of these benign tumors and identifying novel drug targets and therapies.

By Leigh MacMillan
VUMC’s new automated biobanking system can store as many as 10 million biospecimens.
April 6, 2022

Major grant renewal to provide five more years of support for VICTR

Vanderbilt University Medical Center has competed successfully for a third renewal of its Clinical and Translational Science Award by the National Institutes of Health.

By Bill Snyder
March 7, 2022

Study finds World Trade Center responders at higher risk for blood cancer-associated mutations

A study by Vanderbilt and New York City researchers found that 9/11 first responders to the World Trade Center have increased levels of mutations that escalate their risk for blood cancers or cardiovascular disease

By Tom Wilemon
January 10, 2022

Nashville Biosciences and Illumina announce agreement to establish preeminent clinico-genomic resource for life sciences research & development

Nashville Biosciences, a wholly-owned subsidiary of Vanderbilt University Medical Center, has announced an agreement with Illumina, a leading genomic technology company, to realize the full potential of VUMC’s DNA databank, BioVU.

By Bill Snyder
December 2, 2021

Gene discoveries give new hope to people who stutter

New research shows the potential to identify therapeutic directions that could improve outcomes for people who stutter.

By Bill Snyder
December 2, 2021

Study links depression scores, white blood cell count

By Emily Stembridge
September 1, 2021

Initiative helps physicians interpret genetic test results

A new institutional initiative will offer a secure and easy way for physicians at Vanderbilt University Medical Center to ask for help interpreting genetic test results for their patients.
By Nancy Humphrey
July 22, 2021

For more precise drug treatments, ‘squeeze’ the genome: study finds

Large-scale studies will be required to identify the complexity of genetic variations that affect how patients respond to a given drug and whether they will have side effects, according to researchers at Vanderbilt University Medical Center.
By Bill Snyder
July 12, 2021

Probing statin-associated diseases with genetics

Vanderbilt researchers used genetics tools and biobanks with linked electronic health records to explore the associations between statins and noncardiovascular diseases.
By Leigh MacMillan
July 8, 2021

Study finds genetic risk factors for severe COVID-19 illness

A massive worldwide collaboration including researchers from Vanderbilt University Medical Center (VUMC) has identified several genetic factors associated with SARS-CoV-2 infection and severe COVID-19 illness.
By Bill Snyder
July 8, 2021

Genetics of hydrocephalus

Fluid build-up in the brain — hydrocephalus — increases pressure and risk for brain damage; Vanderbilt researchers have now identified genes and signaling pathways associated with the condition.
By Leigh MacMillan
June 17, 2021

Drug allergy labels in medical records power searches for gene-drug associations

By Paul Govern
March 15, 2021

Roden honored with Oscar B. Hunter Career Award in Therapeutics

Dan Roden, MD, Senior Vice President for Personalized Medicine at Vanderbilt University Medical Center, received the Oscar B. Hunter Career Award in Therapeutics last week at the virtual annual meeting of the American Society for Clinical Pharmacology and Therapeutics.
By Leigh MacMillan